At the 2025 Alzheimer's Association International Conference, NewAmsterdam Pharma presented data from the Broadway trial highlighting its cholesterol-lowering drug obicetrapib's ability to reduce Alzheimer's biomarker p-tau217 and other related markers, particularly in at-risk populations. Additionally, Eisai and Biogen reported data supporting the subcutaneous autoinjector formulation of Leqembi (lecanemab), projected to improve patient use and adherence if approved. Longitudinal studies suggest amyloid-clearing therapies may confer increasing benefits over time, advancing the therapeutic landscape in Alzheimer’s disease despite remaining efficacy uncertainties.